Alnylam Pharmaceuticals annual debt-to-assets ratio
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Debt-to-Assets Ratio Growth & History (ALNY)
Alnylam Pharmaceuticals's debt-to-assets ratio was 0.26 for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.26 | −0.05 | −15.79% |
| 2024 | 2024-12-31 | 0.31 | −0.04 | −10.32% |
| 2023 | 2023-12-31 | 0.34 | −0.03 | −8.45% |
| 2022 | 2022-12-31 | 0.37 | 0.28 | +321.36% |
| 2021 | 2021-12-31 | 0.09 | −0.06 | −42.24% |
| 2020 | 2020-12-31 | 0.15 | 0.03 | +20.59% |
| 2019 | 2019-12-31 | 0.13 | — | — |
Alnylam Pharmaceuticals quarterly debt-to-assets ratio
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.23 | −0.06 | −19.74% |
| Q1 2026 | 2026-03-31 | 0.25 | −0.06 | −19.66% |
| Q4 2025 | 2025-12-31 | 0.26 | −0.05 | −15.79% |
| Q3 2025 | 2025-09-30 | 0.27 | −0.04 | −12.89% |
| Q2 2025 | 2025-06-30 | 0.28 | −0.04 | −12.63% |
| Q1 2025 | 2025-03-31 | 0.31 | −0.03 | −9.21% |
| Q4 2024 | 2024-12-31 | 0.31 | −0.04 | −10.32% |
| Q3 2024 | 2024-09-30 | 0.31 | −0.03 | −9.21% |
| Q2 2024 | 2024-06-30 | 0.33 | −0.06 | −15.83% |
| Q1 2024 | 2024-03-31 | 0.34 | −0.05 | −12.59% |
| Q4 2023 | 2023-12-31 | 0.34 | −0.03 | −8.45% |
| Q3 2023 | 2023-09-30 | 0.34 | −0.03 | −8.95% |
| Q2 2023 | 2023-06-30 | 0.39 | 0.09 | +29.82% |
| Q1 2023 | 2023-03-31 | 0.39 | 0.10 | +34.27% |
| Q4 2022 | 2022-12-31 | 0.37 | 0.28 | +321.36% |
| Q3 2022 | 2022-09-30 | 0.37 | 0.16 | +70.99% |
| Q2 2022 | 2022-06-30 | 0.30 | 0.08 | +37.21% |
| Q1 2022 | 2022-03-31 | 0.29 | 0.13 | +82.00% |
| Q4 2021 | 2021-12-31 | 0.09 | −0.06 | −42.24% |
| Q3 2021 | 2021-09-30 | 0.22 | 0.12 | +119.85% |
| Q2 2021 | 2021-06-30 | 0.22 | 0.12 | +132.26% |
| Q1 2021 | 2021-03-31 | 0.16 | 0.03 | +19.12% |
| Q4 2020 | 2020-12-31 | 0.15 | 0.03 | +20.59% |
| Q3 2020 | 2020-09-30 | 0.10 | −0.02 | −16.89% |
| Q2 2020 | 2020-06-30 | 0.09 | −0.02 | −17.26% |
| Q1 2020 | 2020-03-31 | 0.13 | −0.01 | −10.01% |
| Q4 2019 | 2019-12-31 | 0.13 | — | — |
| Q3 2019 | 2019-09-30 | 0.12 | — | — |
| Q2 2019 | 2019-06-30 | 0.11 | — | — |
| Q1 2019 | 2019-03-31 | 0.15 | — | — |
Alnylam Pharmaceuticals debt-to-assets ratio trends
Over the last five fiscal years, Alnylam Pharmaceuticals's debt-to-assets ratio increased from 0.15 to 0.26, a change of 0.10. The latest reported quarter, Q2 2026, shows 0.23.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗Community posts
Alnylam’s product sales jump 52% as it enlarges a pivotal heart-disease trial
Alnylam ($ALNY) reported third-quarter 2026 product revenue of $1.29 billion, up 52%, led by Amvuttra and Onpattro’s combined $1.15 billion contribution. Total revenue increased a slower 17% to $1.46 billion because collaboration revenue de ...
